Vitamin D pills eased eczema in trials of children and adults

Atopic dermatitis, the most common name on an eczema diagnosis, is a chronic inflammatory skin disease affecting up to 20% of children and 10% of adults worldwide. Managing it is often a grind of flare-ups and creams, so a cheap, widely available supplement that genuinely reduced severity would matter to a lot of people. Existing research suggests a correlation between blood vitamin D levels and how severe the condition is, which raises the obvious next question: does supplementing vitamin D actually improve the skin? This review set out to pool the randomised trial evidence in both children and adults.

The authors searched PubMed, EMBASE and Cochrane in April 2024 for randomised controlled trials comparing vitamin D supplementation with a control group in people with atopic dermatitis. Eleven trials with a combined 686 participants qualified for inclusion. The trials measured disease severity using established clinical scales, either the SCOring Atopic Dermatitis index or the Eczema Area and Severity Index. Risk of bias in the included studies was assessed using the Cochrane risk-of-bias tool for randomised trials, and results were pooled across studies.

Vitamin D supplementation significantly reduced atopic dermatitis severity compared with control groups. The pooled result was a standardised effect of 0.41 in favour of the vitamin D groups, measured on the SCORAD and EASI severity scales. The benefit appeared in trials spanning both children and adults. The trials disagreed with each other to a moderate degree, and the authors caution that larger-scale and longer-term studies are still needed to confirm the conclusion.

This pooled analysis strengthens a thread of research linking vitamin D status with eczema severity, moving it from correlation towards trial evidence that supplementing can help. It does not settle the question: the combined sample remains modest, the degree of benefit varied between trials, and the review itself calls for bigger and longer studies. Open questions include who benefits most, whether a person's starting vitamin D level matters, and how supplementation compares with or adds to standard treatments. None of that is answered by the data pooled here.

If eczema affects you or your family, this is worth knowing: across eleven randomised trials, vitamin D supplementation reduced measured disease severity compared with controls. It is information rather than a treatment plan, since the review cannot say which dose, duration or starting level makes the difference, and it positions vitamin D as a possible complement to standard care rather than a replacement for it. For anyone tempted to act on it, a conversation with whoever manages the condition remains the sensible route.